A Phase 1 interventional study of Budoprutug in Systemic Lupus Erythematosus, sponsored by Climb Bio, Inc.. Recruiting at 18 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Climb Bio, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Lupus Erythematosus, Systemic with a site in Ukraine — 4 open to participants now, 9 under way, 6 of them phase 3. Lupus Erythematosus, Systemic · Ukraine.
Among the 36 studies in Lupus Erythematosus, Systemic with a site in Ukraine, this one is the 34th largest by planned enrollment, is one of 2 that started in 2025, is one of 4 in phase 1, and was the 35th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →4 of the 36 studies in Lupus Erythematosus, Systemic with a site in Ukraine are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Ukraine, United States, Australia and 7 more countries
Ages 18–65
Viatris Innovation GmbH · Sites in Ukraine, United States, Argentina and 23 more countries
Ages 18–75
Biogen · Sites in Ukraine, United States, Argentina and 25 more countries
Ages 18+
A study can be open while its sites in Ukraine have not opened yet or have stopped. Only those recruiting at a site in Ukraine →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 18 · Phase 3 15 · Phase 4 1
First in 2004; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 331 across the 36 interventional studies. Of the 27 that completed or were terminated, 21 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 36 have an industry lead sponsor. The 10 most frequent:
Climb Bio, Inc. is the lead sponsor of 6 studies on the registry; 5 are open to participants now.
Climb Bio, Inc. has 1 study filed under Lupus Erythematosus, Systemic — fewer than ten, so there is no comparison to draw.
3 of the studies in Lupus Erythematosus, Systemic with a site in Ukraine that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05672576Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus | 2026-12-31 |
| NCT05648500Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | 2027-03-31 |
| NCT07011043Climb Bio, Inc.A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE) | 2027-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies in Lupus Erythematosus, Systemic with a site in Ukraine, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main objective is to assess the safety and tolerability of budoprutug in adults with SLE. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.
Budoprutug is a humanized, immunoglobulin (Ig) G1 monoclonal antibody that selectively binds to CD19 and is projected to deplete targeted cells through antibody-dependent cellular cytotoxicity. This Phase 1b, open-label study will evaluate budoprutug administered as a single intravenous infusion in ascending dose cohorts of patients aged 18 years and above with active, seropositive SLE and inadequate response to standard therapy. The study will also assess the pharmacokinetics, pharmacodynamics and early indications of efficacy of budoprutug in SLE, where pharmacodynamics will be evaluated as the change in the number of B cells and immunoglobulins (antibodies) in the blood over time following a single infusion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Budoprutug
Drug: Budoprutug
Drug: Budoprutug
Drug: Budoprutug
Single IV dose of study product on Day 1 of study
Also known as: TNT119
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Number of participants experiencing TEAEs, graded per NCI CTCAE v5.0.
Time frame: Up to Week 24
Incidence of Clinical Laboratory Abnormalities
Number of participants with clinically significant laboratory abnormalities.
Time frame: Up to Week 24
Change from Baseline in Systolic Blood Pressure
Mean change from baseline in systolic blood pressure (mmHg).
Time frame: Up to Week 24
Change from Baseline in Diastolic Blood Pressure
Mean change from baseline in diastolic blood pressure (mmHg).
Time frame: Up to Week 24
Change from Baseline in Heart Rate
Mean change from baseline in heart rate (bpm).
Time frame: Up to Week 24
Change from Baseline in Respiratory Rate
Mean change from baseline in respiratory rate.
Time frame: Up to Week 24
Change from Baseline in Body Temperature
Mean change from baseline in body temperature (°C).
Time frame: Up to Week 24
Change from Baseline in PR Interval
Mean change from baseline in PR interval (ms).
Time frame: Up to Week 24
Change from Baseline in QRS Duration
Mean change from baseline in QRS duration (ms).
Time frame: Up to Week 24
Change from Baseline in QT Interval
Mean change from baseline in QT interval (ms).
Time frame: Up to Week 24
Change from Baseline in QTc Interval
Mean change from baseline in corrected QT interval (QTc).
Time frame: Up to Week 24
Area Under the Curve (AUC) of Budoprutug
Measurement of the area under the drug concentration-time curve.
Time frame: Up to Week 24
Maximum Observed Plasma Concentration (Cmax)
Measurement of the maximum observed plasma concentration.
Time frame: Up to Week 24
Time to Maximum Observed Concentration (Tmax)
Measurement of the time to maximum observed concentration.
Time frame: Up to Week 24
Terminal Half-Life (T1/2)
Measurement of the terminal half-life in days.
Time frame: Up to Week 24
Apparent Clearance (CL/F) of budoprutug
Measurement of the apparent clearance in L/hour.
Time frame: Up to Week 24
Volume of Distribution (Vd)
Measurement of the volume of distribution in liters.
Time frame: Up to Week 24
Change from Baseline in Circulating B Cell Count
Change in absolute number of CD19+ B cells in peripheral blood.
Time frame: Up to Week 24
Incidence of Anti-Drug Antibodies (ADAs)
Number of participants with detectable ADAs.
Time frame: Up to Week 24
ADA Titer Over Time
Measurement of ADA titer over time.
Time frame: Up to Week 24
Change from Baseline in BILAG-2004 Score
Measurement of change in BILAG-2004 score from baseline.
Time frame: Up to Week 24
Change from Baseline in SLEDAI-2K Score
Measurement of change in SLEDAI-2K score from baseline.
Time frame: Up to Week 24
Change from Baseline in Physician's Global Assessment
Measurement of change in Physician's Global Assessment score from baseline.
Time frame: Up to Week 24
Proportion of Participants Achieving SRI-4 Response
Percentage of participants achieving SRI-4 response.
Time frame: Up to Week 24
Change from Baseline in Urine Protein Creatinine Ratio (UPCR)
Measurement of change in UPCR from baseline.
Time frame: Up to Week 24
Time to Renal Response
Measurement of time to renal response in weeks.
Time frame: Up to Week 24
Proportion of Participants with Complete or Partial Renal Response
Percentage of participants with complete or partial renal response.
Time frame: Up to Week 24
Change from Baseline in FACIT-Fatigue Score
Measurement of change in FACIT-Fatigue score from baseline.
Time frame: Up to Week 24
Started Jul 2025 (actual). Primary completion is estimated for Apr 2027, 21 months after the start.
Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 21 months is below that.
Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Budoprutug
Lupus Erythematosus, Systemic →
Climb Bio, Inc.